Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) Director Ramkumar Mandalam sold 5,622 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $7.06, for a total transaction of $39,691.32. Following the sale, the director now owns 77,089 shares of the company's stock, valued at approximately $544,248.34. This trade represents a 6.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Cryoport Stock Up 1.9%
NASDAQ CYRX traded up $0.13 during mid-day trading on Wednesday, hitting $6.91. The company's stock had a trading volume of 433,503 shares, compared to its average volume of 531,081. The firm has a market capitalization of $346.45 million, a price-to-earnings ratio of -2.04 and a beta of 1.85. The company's 50 day simple moving average is $6.00 and its 200 day simple moving average is $6.73. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a twelve month low of $4.58 and a twelve month high of $11.20.
Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. Analysts anticipate that Cryoport, Inc. will post -0.99 earnings per share for the current year.
Institutional Trading of Cryoport
Institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. grew its holdings in Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after buying an additional 2,120 shares in the last quarter. Lazard Asset Management LLC purchased a new position in Cryoport during the 4th quarter worth $51,000. Quarry LP bought a new stake in shares of Cryoport in the 4th quarter worth $69,000. SBI Securities Co. Ltd. raised its holdings in shares of Cryoport by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after purchasing an additional 10,975 shares during the last quarter. Finally, CWM LLC lifted its position in shares of Cryoport by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock valued at $69,000 after purchasing an additional 10,591 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently commented on CYRX shares. Roth Mkm reaffirmed a "buy" rating and set a $15.00 target price on shares of Cryoport in a research note on Tuesday, April 1st. UBS Group increased their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Cryoport in a research report on Thursday, May 8th. Morgan Stanley dropped their target price on shares of Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Finally, Guggenheim restated a "buy" rating and issued a $10.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Cryoport presently has an average rating of "Moderate Buy" and a consensus price target of $11.00.
Read Our Latest Stock Analysis on Cryoport
About Cryoport
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Articles
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
